Literature DB >> 23568790

Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants.

Freek W A Verheugt1.   

Abstract

Patients with atrial fibrillation (AF) have an increased stroke risk compared with those in sinus rhythm, although the absolute risk for individual patients is modulated by the presence of various additional risk factors. Patient selection for oral anticoagulation for stroke prevention is based on risks of stroke and bleeding. Although CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack) is the most widely used scheme for evaluating stroke risk in patients with AF, several other stroke risk factors are not included; therefore, many patients' stroke risk may be underestimated, contributing to the underuse of anticoagulants. Furthermore, a substantial proportion of patients are categorized as being at moderate risk (CHADS2 = 1), and there has been some ambiguity regarding optimum thromboprophylaxis in this group. The refinement of CHADS2 , CHA2 DS2 -VASc (Congestive heart failure, Hypertension, Age 75 years [2 points], Diabetes mellitus, Stroke or transient ischemic attack [2 points], Vascular disease, Age 65 to 74 years, Sex category [female]), considers additional risk factors. Its main advantage is its ability to identify patients truly at low risk of thromboembolism (CHA2 DS2 -VASc = 0), who are unlikely to benefit from antithrombotic therapy. For all others, an oral anticoagulant may be the preferred approach, simplifying clinical decision making. Implementation of CHA2 DS2 -VASc may also result in an increased proportion of patients receiving anticoagulation. The emergence of newer oral anticoagulants that can be given without routine coagulation monitoring, with improved benefit-risk profiles vs vitamin K antagonists, promises to simplify therapy for patients with AF at risk of stroke. This, coupled with advances in stroke risk stratification, is expected to improve patient outcomes and reduce the burden of AF-related stroke.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568790      PMCID: PMC6649625          DOI: 10.1002/clc.22122

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  43 in total

1.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

2.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; A John Camm; S Bertil Olsson; Dietrich Andresen; D Wyn Davies; Stuart Cobbe; Günter Breithardt; Jean-Yves Le Heuzey; Martin H Prins; Samuel Lévy; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2005-10-04       Impact factor: 29.983

3.  Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; Gregory Y H Lip; S Bertil Olsson; Martin H Prins; Fred H Nieman; José López-Sendón; Panos E Vardas; Etienne Aliot; Massimo Santini; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2006-05-26       Impact factor: 29.983

4.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

5.  Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.

Authors:  Albert L Waldo; Richard C Becker; Victor F Tapson; Kevin J Colgan
Journal:  J Am Coll Cardiol       Date:  2005-10-10       Impact factor: 24.094

6.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

Authors:  S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf
Journal:  Lancet       Date:  2006-06-10       Impact factor: 79.321

7.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

Review 8.  Does heart failure exacerbation increase response to warfarin? A critical review of the literature.

Authors:  Timothy H Self; Anne B Reaves; Carrie S Oliphant; Chris Sands
Journal:  Curr Med Res Opin       Date:  2006-11       Impact factor: 2.580

9.  Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.

Authors:  Brian F Gage; Carl van Walraven; Lesly Pearce; Robert G Hart; Peter J Koudstaal; B S P Boode; Palle Petersen
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

10.  Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study.

Authors:  Dominique Deplanque; Didier Leys; Lucilla Parnetti; Reinhold Schmidt; Jose Ferro; Jacques De Reuck; Jean-Louis Mas; Virgilio Gallai
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

View more
  1 in total

1.  Gender differences in patients with atrial fibrillation.

Authors:  Ralph F Bosch; David Pittrow; Anne Beltzer; Irmtraut Kruck; Wilhelm Kirch; Annette Kohlhaussen; Hendrik Bonnemeier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-08-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.